On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.

The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.

The team that advised Day One on the transaction includes Julia Minitti, Luis Perla, Ying Chen, Maya Skubatch, and Tina Xiang.

For more information, please see Day One’s news release. Additional coverage can be found on The Wall Street Journal.